• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    6/3/22 1:48:32 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LCI alert in real time by email
    SC 13G/A 1 LANNETT_COMPANY_INC.htm FILING LANNETT COMPANY, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 03)*
     
    LANNETT COMPANY, INC. 

    (Name of Issuer)
     
    Common Stock, $0.001 par value

    (Title of Class of Securities)
     
    516012101

    (CUSIP Number)
     
    May 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  516012101            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      91,632
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      109,037
         
    8   SHARED DISPOSITIVE POWER
       
      0
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      109,037
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      0.2 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    LANNETT COMPANY, INC.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    1150 Northbrook Drive Suite 155
    Trevose, PA 19053


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.001 par value


     
    (e)
    CUSIP Number
     
     
    516012101


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 109,037


     
    (b)
    Percent of class: 0.2 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 91,632


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 109,037


     
    (iv)
    Shared power to dispose or to direct the disposition of: 0


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    JPMorgan Chase Bank, National Association
    J.P. Morgan Investment Management Inc.
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: June 03, 2022
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $LCI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LCI

    DatePrice TargetRatingAnalyst
    8/31/2021$7.00 → $6.00Neutral
    Roth Capital
    More analyst ratings

    $LCI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling

    9/24/24 4:39:48 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MYCOPHENOLATE MOFETIL issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS

    8/15/24 4:43:42 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:

    7/17/24 4:37:21 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Chapman John C bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 13% to 174,324 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/18/22 4:09:03 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Lepore Patrick G bought $49,000 worth of shares (100,000 units at $0.49), increasing direct ownership by 21% to 587,145 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:16:01 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Crew Timothy C bought $7,200 worth of shares (15,000 units at $0.48), increasing direct ownership by 3% to 604,291 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:14:53 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    SEC Filings

    View All

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:08 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:20 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:14 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $6.00 from $7.00 previously

    8/31/21 8:50:46 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $7.00 from $7.50 previously

    6/10/21 9:57:43 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT SHARES UPDATE

    Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure to Pay Interest on Convertible Notes TREVOSE, Pa., April 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

    4/4/23 6:55:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Financials

    Live finance-specific insights

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

    TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a

    1/25/23 6:52:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/10/23 9:46:33 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    6/3/22 1:48:32 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/11/22 8:19:58 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care